Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Theravance Biopharma, Inc. (TBPH)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Theravance Biopharma, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1583107.
Total stock buying since 2015: $29,986,832,769,323.
Total stock sales since 2015: $9,034,594.
Total stock option exercises since 2015: $0.
Table 3. Detailed insider trading at Theravance Biopharma, Inc. (TBPH)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-06-02 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 24,000 | 11.00 | 264,000 |
| 2025-04-21 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 4,000 | 9.00 | 36,000 |
| 2025-01-21 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 4,000 | 9.00 | 36,000 |
| 2024-11-11 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 4,000 | 9.00 | 36,000 |
| 2024-08-07 | Samaha Eli (10% Owner) | Buy | 999,800 | 7.80 | 7,798,440 |
| 2024-07-10 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 4,000 | 9.00 | 36,000 |
| 2024-05-01 | Samaha Eli (10% Owner) | Buy | 1,499,124 | 8.75 | 13,117,335 |
| 2024-02-22 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 1,254 | 8.71 | 10,922 |
| 2023-11-21 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 1,378 | 10.29 | 14,179 |
| 2023-11-14 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,482 | 10.22 | 25,366 |
| 2023-10-16 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,482 | 9.03 | 22,412 |
| 2023-09-14 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,482 | 9.89 | 24,546 |
| 2023-08-22 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 1,807 | 9.47 | 17,112 |
| 2023-08-11 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,322 | 9.99 | 23,196 |
| 2023-07-14 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,322 | 9.84 | 22,848 |
| 2023-06-14 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,322 | 10.69 | 24,822 |
| 2023-06-08 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 1,790 | 11.13 | 19,922 |
| 2023-05-15 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,322 | 11.26 | 26,145 |
| 2023-04-14 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,323 | 11.88 | 27,597 |
| 2023-03-14 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,323 | 10.32 | 23,973 |
| 2023-03-09 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 4,000 | 10.20 | 40,800 |
| 2023-03-06 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 2,323 | 10.05 | 23,346 |
| 2022-12-01 | Graham Richard A (SVP, RESEARCH & DEVELOPMENT) | Sale | 4,168 | 10.73 | 44,722 |
| 2022-08-16 | Graham Richard A (SVP, DEVELOPMENT) | Sale | 4,906 | 9.71 | 47,642 |
| 2022-08-09 | Graham Richard A (SVP, DEVELOPMENT) | Sale | 15,086 | 8.79 | 132,605 |
| 2022-05-23 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 1,081 | 8.93 | 9,653 |
| 2022-02-28 | Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) | Sale | 2,356 | 10.16 | 23,946 |
| 2021-03-09 | Worboys Philip D (SVP, Research & Transl Science) | Sale | 8,829 | 20.00 | 176,580 |
| 2020-12-14 | Graham Richard A (SVP, Development) | Sale | 7,500 | 19.47 | 146,055 |
| 2020-12-03 | Worboys Philip D (SVP, Research & Transl Science) | Sale | 4,246 | 18.00 | 76,428 |
| 2020-08-21 | Haumann Brett K (Chief Medical Officer) | Sale | 25,000 | 18.29 | 457,250 |
| 2020-08-20 | Worboys Philip D (SVP, Research & Transl Science) | Sale | 17,103 | 18.00 | 307,854 |
| 2019-12-12 | Sabesan Vijay (SVP, Technical Operations) | Sale | 1,027 | 21.03 | 21,597 |
| 2019-05-17 | O'connor Donal | Sale | 2,673 | 20.19 | 53,967 |
| 2019-05-16 | O'connor Donal | Sale | 1,327 | 21.00 | 27,867 |
| 2019-03-05 | Hegde Sharathchandra S (SVP, Research) | Sale | 5,690 | 24.50 | 139,405 |
| 2019-03-04 | Hegde Sharathchandra S (SVP, Research) | Sale | 3,343 | 25.06 | 83,762 |
| 2018-09-12 | Worboys Philip D (SVP, Translational Science) | Sale | 6,393 | 28.50 | 182,200 |
| 2018-08-27 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 7,119 | 27.71 | 197,281 |
| 2018-08-15 | Gala Renee D (SVP, Chief Financial Officer) | Sale | 41,539 | 27.07 | 1,124,336 |
| 2018-08-14 | Gala Renee D (SVP, Chief Financial Officer) | Sale | 2,204 | 27.74 | 61,136 |
| 2018-08-08 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 25,355 | 27.85 | 706,187 |
| 2018-08-07 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 5,945 | 28.51 | 169,503 |
| 2018-06-08 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 3,900 | 23.66 | 92,258 |
| 2018-06-06 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 10,140 | 24.09 | 244,272 |
| 2018-05-21 | Malkiel Burton G | Buy | 1,000 | 22.54 | 22,540 |
| 2018-05-18 | Gala Renee D (SVP, Chief Financial Officer) | Sale | 10,000 | 24.29 | 242,880 |
| 2017-09-06 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 14,670 | 30.77 | 451,351 |
| 2017-08-21 | Pasqualone Frank (SVP, Chief Comm Ops Officer) | Buy | 4,000 | 26.34 | 105,360 |
| 2017-08-11 | Fore Henrietta | Buy | 6,000 | 23.99 | 143,934 |
| 2017-08-11 | Winningham Rick E (Chief Executive Officer) | Buy | 10,000 | 24.50 | 245,000 |
| 2017-08-11 | Whitesides George M | Buy | 4,000 | 24.69 | 98,764 |
| 2017-08-11 | Malkiel Burton G | Buy | 30,000 | 24.59 | 737,670 |
| 2017-03-07 | Haumann Brett K (SVP Clin Dev & Chief Med Ofc) | Sale | 424 | 30.80 | 13,059 |
| 2017-03-06 | Haumann Brett K (SVP Clin Dev & Chief Med Ofc) | Sale | 13,576 | 31.52 | 427,915 |
| 2017-03-03 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 26,829 | 31.86 | 854,771 |
| 2016-08-25 | Haumann Brett K (SVP Clin Dev & Chief Med Ofc) | Sale | 4,491 | 27.99 | 125,703 |
| 2016-08-22 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 37,078 | 27.16 | 1,007,038 |
| 2016-08-19 | Haumann Brett K (SVP Clin Dev & Chief Med Ofc) | Sale | 9,509 | 27.97 | 265,966 |
| 2016-08-19 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 4,870 | 28.14 | 137,041 |
| 2016-08-18 | Shafer Bradford J (EVP, Gen. Counsel, Secretary) | Sale | 7,174 | 28.55 | 204,817 |
| 2016-03-14 | Glaxosmithkline Plc | Buy | 1,301,015 | 23,027,965.50 | 29,959,728,534,982 |
| 2015-10-07 | Glaxosmithkline Plc | Buy | 44,574 | 607,543.62 | 27,080,649,317 |
| 2015-08-18 | Lee Junning (Sr. VP, Technical Operations) | Buy | 9,000 | 12.90 | 116,100 |
| 2015-08-18 | Malkiel Burton G | Buy | 10,000 | 12.92 | 129,200 |
| 2015-08-17 | Gala Renee D (SVP, Chief Financial Officer) | Buy | 5,000 | 12.16 | 60,800 |
| 2015-08-17 | Winningham Rick E (Chief Executive Officer) | Buy | 16,860 | 12.13 | 204,511 |
| 2015-08-14 | Winningham Rick E (Chief Executive Officer) | Buy | 63,140 | 11.79 | 744,420 |
| 2015-08-13 | Gala Renee D (SVP, Chief Financial Officer) | Buy | 5,000 | 12.19 | 60,950 |
Insider trading activities including stock purchases, stock sales, and option exercises
of TBPH listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Theravance Biopharma, Inc. (symbol TBPH,
CIK number 1583107) see
the Securities and Exchange Commission (SEC) website.